ERLEADA® (apalutamide) demonstrates statistically significant …
WEB2 days ago · Johnson Johnson (NYSE: JNJ) today announced the results of a landmark real-world, head-to-head study showing that ERLEADA ® (apalutamide) provided a statistically significant overall survival benefit at 24 months compared to enzalutamide in patients with metastatic castration-sensitive prostate cancer (mCSPC). Presented at the 6th European Congress of Oncology Pharmacy (ECOP) in Lisbon ...
Johnson & Johnson's Erleada Shows Improved Overall Survival In …
WEB1 day ago · Wednesday, Johnson & Johnson (NYSE:JNJ) revealed results from a head-to-head study of Erleada (apalutamide) compared to Pfizer Inc’s (NYSE:PFE) Xtandi (enzalutamide). The data showed that ...
ERLEADA demonstrates statistically significant and clinically ...
WEBThe proportion of patients alive at 24 months (87.6 percent) observed in the ERLEADA cohort in this real-world analysis is consistent with that in the Phase 3 TITAN trial (82.4 percent). 1 TITAN demonstrated a statistically significant superior overall survival benefit of ERLEADA plus androgen deprivation therapy (ADT) compared to ADT alone at ...
J&J’s Erleada provides survival edge over Astellas’ Xtandi
WEB1 day ago · The study looked at treatment outcomes for more than 3,700 patients and found that Erleada reduced the risk of death by 23% over Xtandi after 24 months, J&J said in a Tuesday release. The ...
Apalutamide associated with improved survival vs enzalutamide in …
WEB2 days ago · Apalutamide (Erleada) was found to provide a significant improvement in overall survival (OS) at 24 months compared with enzalutamide (Xtandi) in the treatment of androgen receptor pathway inhibitor (ARPI)-naïve patients with metastatic castration-sensitive prostate cancer (mCSPC), according to data from a head-to-head retrospective analysis presented at the 6th European Congress of Oncology ...
Phase 2 data for ERLEADA® (apalutamide) plus androgen …
WEBSAN ANTONIO, May 3, 2024 – Johnson & Johnson announced today results from the open-label, single-arm Phase 2 Apa-RP study evaluating adjuvant treatment with ERLEADA ® (apalutamide) and androgen deprivation therapy (ADT) in patients with HRLPC who have undergone radical prostatectomy (RP).
Phase 2 data for ERLEADA® (apalutamide) plus androgen …
WEBMay 3, 2024 · Johnson & Johnson announced today results from the open-label, single-arm Phase 2 Apa-RP study evaluating adjuvant treatment with ERLEADA® (apalutamide) and androgen deprivation therapy (ADT) in...
JNJ's Erleada Shows Statistically Significant Overall Survival In ...
WEB1 day ago · Johnson & Johnson (), Wednesday announced results from a head-to-head study, demonstrating statistically significant overall survival benefit in patients on Erleada at 24 months compared to Enzalutamide in patients with metastatic castration-sensitive prostate cancer.The analysis found that patients who initiated Erleada as their first androgen receptor pathway inhibitor had a statistically ...
ERLEADA® (apalutamide) demonstrates statistically significant …
WEB1 day ago · The proportion of patients alive at 24 months (87.6 percent) observed in the ERLEADA ® cohort in this real-world analysis is consistent with that in the Phase 3 TITAN trial (82.4 percent). 1 ...
FDA approves new treatment for a certain type of prostate cancer …
WEBThe U.S. Food and Drug Administration today approved Erleada (apalutamide) for the treatment of patients with prostate cancer that has not spread (non-metastatic), but that continues to grow...